AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

IN THE CLAIMS:

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

1. (Currently Amended) A composition comprising

i) a sulphamate compound having the formula



wherein each of R_1 and R_2 is independently selected from H or a hydrocarbyl group, and wherein an (oxy)hydrocarbyl group is attached to the 2 position of the A ring of the steroidal structure; and

ii) an apoptosis inducer;

wherein the apoptosis inducer is a tumour necrosis factor-related apoptosis inducing ligand that binds to TRAIL-R1 or TRAIL-R2.

2-4. (Cancelled)

5. (Previously Presented) The composition according to claim 1, wherein the ligand is TRAIL/Apo-2L.

6. (Previously Presented) The composition according to claim 1, wherein the apoptosis inducer is capable of interacting with a tumour necrosis factor-related apoptosis inducing ligand receptor.

7-18. (Cancelled)

19. (Previously Presented) The composition according to claim 1, wherein the (oxy)hydrocarbyl group is a group of the formula $C_{1-6}O$.

20. (Original) The composition according to claim 19, wherein the group of the formula $C_{1-6}O$ is a methoxy group.

21. (Original) The composition according to claim 1, wherein the sulphamate compound is 2-methoxyoestrone-3-O-sulphamate.

22. (Previously Presented) The composition according to claim 1, wherein the hydrocarbyl group is a group of the formula C_{1-6}.

23. (Original) The composition according to claim 22, wherein the group of the formula C_{1-6} is an ethyl group

24. (Original) The composition according to claim 1, wherein the sulphamate compound is 2-ethyloestrone-3-O-sulphamate.

25. (Cancelled)

26. (Original) The composition according to claim 1, wherein the sulphamate compound is an inhibitor of oestrone sulphatase (E.C. 3.1.6.2).

27. (Original) The composition according to claim 1, wherein if the sulphamate group of the sulphamate compound were to be replaced with a sulphate group to form a sulphate

compound, then the sulphate compound would be hydrolysable by a steroid sulphatase enzyme (E.C.3.1.6.2).

28. (Original) The composition according to claim 1, wherein if the sulphamate group of the sulphamate compound were to be replaced with a sulphate group to form a sulphate compound, and the sulphate compound were incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at pH 7.4 and 37°C, it would provide a K_m value of less than 50 mM.

29. (Original) The composition according to claim 1, wherein if the sulphamate group of the sulphamate compound were to be replaced with a sulphate group to form a sulphate compound, and the sulphate compound were incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at pH 7.4 and 37°C, it would provide a K_m value of less than 50 μM.

30. (Original) The composition according to claim 1, wherein the sulphamate compound comprises at least two sulphamate groups.

31. (Cancelled)

32. (Original) The composition according to claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier, diluent, or excipient.

33-43. (Cancelled)

44. (Previously Presented) A composition according to claim 1 wherein the sulphamate compound has the formula



45. (Previously Presented) A composition according to claim 1 wherein the sulphamate compound has the formula